πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10421765

Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

The Board of Regents of the University of Texas System Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10420813

Competitive inhibitors of invariant chain expression and/or ectopic clip binding

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10420758

Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10414740

Glutaminase inhibitors and method of use

Agios Pharmaceuticals, Inc. Β· Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10407445

Hepatitis C virus inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10407409

6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10400010

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeu

The Regents of the University of California Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10398706

Heteroaryldiazepine derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392391

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392386

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392376

Heterocyclic inhibitors of ATR kinase

The Board of Regents of the University of Texas System Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391175

BET bromodomain inhibitors and therapeutic methods using the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392368

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391097

Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

VTV THERAPEUTICS LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391095

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10385080

STAT6 inhibitors

The Board of Regents of the University of Texas System Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10385031

Substituted piperazines as selective HDAC1,2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10377772

Macrocyclic LRRK2 kinase inhibitors

Oncodesign SA Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376515

Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activati

Northwestern University Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376510

2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of ca

Agios Pharmaceuticals, Inc. Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370371

Substituted pyrimidine Bmi-1 inhibitors

PTC THERAPEUTICS, INC. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370367

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370360

Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370333

Sulfonamide compounds and uses as TNAP inhibitors

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted